Verastem (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company’s product candidate FAK inhibitor, VS-6063, is in phase I study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a phase II study in patients with non-small cell lung cancer; a phase II trial preceding surgery in mesothelioma; and a phase I/Ib clinical trial in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. For more information, visit the company’s website at www.verastem.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com